408 related articles for article (PubMed ID: 31992691)
1. Venetoclax plus hypomethylating agents or low-dose cytarabine in acute myeloid leukemia: all that glitters is gold?
Ferrara F
Blood Cancer J; 2020 Jan; 10(1):10. PubMed ID: 31992691
[No Abstract] [Full Text] [Related]
2. More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabine.
Aldoss I; Marcucci G
Chin Clin Oncol; 2019 Oct; 8(S1):S25. PubMed ID: 31684734
[No Abstract] [Full Text] [Related]
3. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis.
Bewersdorf JP; Giri S; Wang R; Williams RT; Tallman MS; Zeidan AM; Stahl M
Haematologica; 2020 Nov; 105(11):2659-2663. PubMed ID: 33131256
[No Abstract] [Full Text] [Related]
4. Treatment of refractory acute myeloid leukaemia during pregnancy with venetoclax, high-dose cytarabine and mitoxantrone.
Karagiannis P; Alsdorf W; Tallarek AC; Blohm ME; Oelrich J; Waizenegger JS; Wolschke C; Hecher K; Singer D; Bokemeyer C; Fiedler W
Br J Haematol; 2021 Jan; 192(2):e60-e63. PubMed ID: 33222152
[No Abstract] [Full Text] [Related]
5. Venetoclax and alvocidib are both cytotoxic to acute myeloid leukemia cells resistant to cytarabine and clofarabine.
Nishi R; Shigemi H; Negoro E; Okura M; Hosono N; Yamauchi T
BMC Cancer; 2020 Oct; 20(1):984. PubMed ID: 33046037
[TBL] [Abstract][Full Text] [Related]
6. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective?
Pollyea DA; Jordan CT
Curr Opin Hematol; 2019 Mar; 26(2):71-76. PubMed ID: 30652974
[TBL] [Abstract][Full Text] [Related]
7. The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia.
Lim B; Yoo D; Chun Y; Go A; Cho KJ; Choi D; Jung ME; Lee HY; Boohaker RJ; Lee JS; Jung D; Choi G
Blood Cancer J; 2022 Apr; 12(4):57. PubMed ID: 35410412
[No Abstract] [Full Text] [Related]
8. Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).
Badar T; Nanaa A; Atallah E; Shallis RM; Guilherme SCC; Goldberg AD; Saliba AN; Patel A; Bewersdorf JP; DuVall AS; Bradshaw D; Abaza Y; Murthy GSG; Palmisiano N; Zeidan AM; Kota V; Litzow MR
Blood Cancer J; 2024 Feb; 14(1):32. PubMed ID: 38378617
[TBL] [Abstract][Full Text] [Related]
9. Hypomethylating agents with venetoclax: have we discovered the holy grail?
Gutman JA; Pollyea DA
Curr Opin Hematol; 2020 Mar; 27(2):76-80. PubMed ID: 31895103
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice.
Apel A; Moshe Y; Ofran Y; Gural A; Wolach O; Ganzel C; Canaani J; Zektser M; Duek A; Stemer G; Hellman I; Basood M; Frisch A; Leibovitch C; Koren-Michowitz M
Am J Hematol; 2021 Jul; 96(7):790-795. PubMed ID: 33836555
[TBL] [Abstract][Full Text] [Related]
11. Is venetoclax the new backbone of acute myeloid leukaemia therapy?
Jain P; Mims AS
Lancet Haematol; 2021 Aug; 8(8):e536-e537. PubMed ID: 34329570
[No Abstract] [Full Text] [Related]
12. Venetoclax-based therapies for acute myeloid leukemia.
Guerra VA; DiNardo C; Konopleva M
Best Pract Res Clin Haematol; 2019 Jun; 32(2):145-153. PubMed ID: 31203996
[TBL] [Abstract][Full Text] [Related]
13. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia.
Morales ML; García-Vicente R; Rodríguez-García A; Reyes-Palomares A; Vincelle-Nieto Á; Álvarez N; Ortiz-Ruiz A; Garrido-García V; Giménez A; Carreño-Tarragona G; Sánchez R; Ayala R; Martínez-López J; Linares M
Leukemia; 2023 Aug; 37(8):1649-1659. PubMed ID: 37422594
[TBL] [Abstract][Full Text] [Related]
14. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
[TBL] [Abstract][Full Text] [Related]
15. Prospects for Venetoclax in Myelodysplastic Syndromes.
Garcia JS
Hematol Oncol Clin North Am; 2020 Apr; 34(2):441-448. PubMed ID: 32089221
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax: A new wave in hematooncology.
Mihalyova J; Jelinek T; Growkova K; Hrdinka M; Simicek M; Hajek R
Exp Hematol; 2018 May; 61():10-25. PubMed ID: 29477371
[TBL] [Abstract][Full Text] [Related]
17. Venetoclax in acute myeloid leukemia.
Bruzzese A; Martino EA; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Investig Drugs; 2023 Apr; 32(4):271-276. PubMed ID: 36933006
[No Abstract] [Full Text] [Related]
18. Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia.
Kennedy VE; Hui G; Azenkot T; Gaut D; Wieduwilt MJ; Oliai C; Jonas BA; Mittal V; Logan AC; Muffly LS; Mannis GN
Am J Hematol; 2022 Jun; 97(6):E191-E194. PubMed ID: 35266185
[No Abstract] [Full Text] [Related]
19. Venetoclax in the treatment of acute myeloid leukemia: Beyond VIALE-A.
Gangat N; Tefferi A
Am J Hematol; 2024 Apr; 99(4):515-518. PubMed ID: 38375926
[TBL] [Abstract][Full Text] [Related]
20. Venetoclax in AML: Where We Are and Where We Are Headed.
Pollyea DA
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S25-S26. PubMed ID: 32862856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
